Alice T. Shaw, M.D., Ph.D., is the Chair of the Department of Medical Oncology and Chief of Strategic Partnerships at Dana-Farber Cancer Institute. She is also the George P. and Jean S. Canellos Professor of Medicine at Harvard Medical School. As Department Chair, she leads a world-renowned department of over 400 faculty members who are performing groundbreaking fundamental, translational and clinical research, while also providing exceptional clinical care. In her role as Chief of Strategic Partnerships, she oversees the collaborative efforts between researchers and the life sciences industry to help accelerate the development of innovative new therapies for patients with cancer. Dr. Shaw was previously Vice President and Global Head of Translational Clinical Oncology at Novartis for almost five years. Prior to Novartis, Dr. Shaw was the Director of the Center for Thoracic Cancers at Massachusetts General Hospital (MGH), the Paula O’Keeffe Endowed Chair of Thoracic Oncology at MGH, Co-Leader of the Dana-Farber/Harvard Cancer Center Thoracic Oncology Program, and Professor of Medicine at Harvard Medical School. Since 2008, Dr. Shaw has studied resistance to targeted therapies in the lab and the clinic, and helped develop numerous targeted therapies for patients with oncogene-driven lung cancers, including crizotinib, ceritinib, alectinib, and lorlatinib. Since her return to academia, Dr. Shaw has continued her research in oncogene-driven lung cancers, and is co-founder and co-director of the DFCI Center for RAS Therapeutics.